for relapsed or refractory mantle cell lymphoma
FDA granted accelerated approval to Beqalzi (sonrotoclax) for relapsed or refractory mantle cell lymphoma. The drug enters a category currently led by AbbVie's Venclexta (venetoclax); the differentiation is centered on BCL2 selectivity and the dosing profile.
Mantle cell lymphoma is a non-Hodgkin's lymphoma that starts in the mantle zone of the lymph nodes, where immune cells begin multiplying out of control. Beqalzi (sonrotocl
The goal of this study is to compare how well sonrotoclax plus zanubrutinib works versus zanubrutinib plus placebo in treating adults with relapsed/refractory (R/R) mantle cell lymphoma (MCL). This study will also look at the safety of sonrotoclax plus zanubrutinib versus zanubrutinib plus placebo.
Source: ClinicalTrials.gov